2019-000602-30: A Prospective Phase III Multi-center, Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of “Kamada-AAT for Inhalation” 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate Airflow Limitation (50% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%). |
|
|
| Not yet recruiting | 3 | 220 | Europe, RoW | Kamada -AAT for Inhalation or inhaled AAT (AAT), Nebuliser solution | Kamada Ltd., Kamada Ltd. | Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate Airflow Limitation (50% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), and with no history of two or more moderate or one or more severe exacerbations of COPD during the past year., Treatment and management of adult patients with congenital Alpha Antitrypsin Deficiency., Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
